Use of Quantitative Pharmacology in the Development of HAE1, a High-Affinity Anti-IgE Monoclonal Antibody
Journal Title: The AAPS Journal - Year 2008, Vol 10, Issue 2
Abstract
HAE1, a high-affinity anti-IgE monoclonal antibody, is discussed here as a case study in the use of quantitative pharmacology in the development of a second-generation molecule. In vitro, preclinical, and clinical data from the first-generation molecule, omalizumab, were heavily leveraged in the HAE1 program. A preliminary mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model for HAE1 was developed using an existing model for omalizumab, together with in vitro binding data for HAE1 and omalizumab. When phase I data were available, the model was refined by simultaneously modeling PK/PD data from omalizumab studies with the available HAE1 phase I data. The HAE1 clinical program was based on knowledge of the quantitative relationship between a pharmacodynamic biomarker, suppression of free IgE, and clinical response (e.g., lower exacerbation rates) obtained in pivotal studies with omalizumab. A clinical trial simulation platform was developed to predict free IgE levels and clinical responses following attainment of a target free IgE level (≤10 IU/ml). The simulation platform enabled selection of four doses for the phase II dose-ranging trial by two independent methods: dose-response non-linear fitting and linear mixed modeling. Agreement between the two methods provided confidence in the doses selected. Modeling and simulation played a large role in supporting acceleration of the HAE1 program by enabling data-driven decision-making, often based on confirmation of projections and/or learning from incoming new data.
Authors and Affiliations
Wendy S. Putnam, Jing Li, Jonas Haggstrom, Chee Ng, Saloumeh Kadkhodayan-Fischer, Melissa Cheu, Yamo Deniz, Henry Lowman, Paul Fielder, Jennifer Visich, Amita Joshi, Nelson “Shasha” Jumbe
Keywords
Related Articles
- EP ID EP681566
- DOI 10.1208/s12248-008-9045-4
- Views 62
- Downloads 0
Fmoc-Conjugated PEG-Vitamin E2 Micelles for Tumor-Targeted Delivery of Paclitaxel: Enhanced Drug-Carrier Interaction and Loading Capacity
The online version of this article (doi:10.1208/s12248-014-9651-2) contains supplementary material, which is available to authorized users.
Improper Selection of a Pre-specified Primary Dose–Response Analysis Delays Regulatory Drug Approval
Dose–response analysis is one of the accepted efficacy endpoints to establish effectiveness. The purpose of this research was to inform selection of an appropriate pre-specified primary dose–response anal...
Estimation of capping incidence by indentation fracture tests
The purpose of this study was to predict the capping tendencies of pharmaceutical powders by creating indentation fracture on compacts. Three sets of binary mixtures containing different concentrations of each ingredient...
Recommendations and Best Practices for Reference Standards and Reagents Used in Bioanalytical Method Validation
The continued globalization of pharmaceutics has increased the demand for companies to know and understand the regulations that exist across the globe. One hurdle facing pharmaceutical and biotechnology companies develop...
Recent Advances in Structure-Based Virtual Screening of G-Protein Coupled Receptors
In addition to the rhodopsin crystal structure, high-resolution crystal structures of ligand-mediated G-protein-coupled receptors (GPCRs) have recently become available, and these have become attractive templates for dev...